IS3023B - 3-((3R,4R)-4-metýl-3-[metýl-(7H-pýrróló[2,3-d]pýrimídín-4-ýl)-amínó]-píperidínýl)-3-oxó-própíónítríl sem prótínkínasahindri - Google Patents

3-((3R,4R)-4-metýl-3-[metýl-(7H-pýrróló[2,3-d]pýrimídín-4-ýl)-amínó]-píperidínýl)-3-oxó-própíónítríl sem prótínkínasahindri

Info

Publication number
IS3023B
IS3023B IS6993A IS6993A IS3023B IS 3023 B IS3023 B IS 3023B IS 6993 A IS6993 A IS 6993A IS 6993 A IS6993 A IS 6993A IS 3023 B IS3023 B IS 3023B
Authority
IS
Iceland
Prior art keywords
methyl
propionitrile
pyrrolo
pyrimidin
piperidinyl
Prior art date
Application number
IS6993A
Other languages
English (en)
Other versions
IS6993A (is
Inventor
Christian Koecher
Glenn Wilcox
Mark Flanagan
Michael MUNCHHOF
Ton Vries
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26968730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS3023(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IS6993A publication Critical patent/IS6993A/is
Publication of IS3023B publication Critical patent/IS3023B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS6993A 2001-05-31 2003-10-13 3-((3R,4R)-4-metýl-3-[metýl-(7H-pýrróló[2,3-d]pýrimídín-4-ýl)-amínó]-píperidínýl)-3-oxó-própíónítríl sem prótínkínasahindri IS3023B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29477501P 2001-05-31 2001-05-31
US34104801P 2001-12-06 2001-12-06
PCT/IB2002/001905 WO2002096909A1 (en) 2001-05-31 2002-05-29 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors

Publications (2)

Publication Number Publication Date
IS6993A IS6993A (is) 2003-10-13
IS3023B true IS3023B (is) 2020-08-15

Family

ID=26968730

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6993A IS3023B (is) 2001-05-31 2003-10-13 3-((3R,4R)-4-metýl-3-[metýl-(7H-pýrróló[2,3-d]pýrimídín-4-ýl)-amínó]-píperidínýl)-3-oxó-própíónítríl sem prótínkínasahindri

Country Status (52)

Country Link
US (2) US7301023B2 (is)
EP (3) EP1392694A1 (is)
JP (1) JP4381137B2 (is)
KR (5) KR100926875B1 (is)
CN (1) CN1729192A (is)
AP (1) AP1859A (is)
AR (2) AR037321A1 (is)
AT (1) ATE519741T1 (is)
AU (2) AU2002304401C1 (is)
BE (1) BE2017C032I2 (is)
BG (1) BG66489B1 (is)
BR (1) BR0209246A (is)
CA (1) CA2448281C (is)
CL (1) CL2008000762A1 (is)
CR (1) CR10177A (is)
CU (1) CU23337B7 (is)
CY (2) CY1113322T1 (is)
CZ (1) CZ304366B6 (is)
DK (1) DK1666481T3 (is)
EA (2) EA007251B1 (is)
EC (1) ECSP034865A (is)
EE (1) EE05332B1 (is)
ES (2) ES2369226T3 (is)
FR (1) FR17C1031I2 (is)
GE (1) GEP20063784B (is)
GT (2) GT200200100A (is)
HR (1) HRP20030943B1 (is)
HU (2) HU230876B1 (is)
IL (1) IL158588A0 (is)
IS (1) IS3023B (is)
LT (1) LTC1666481I2 (is)
LU (1) LUC00031I2 (is)
MA (1) MA27029A1 (is)
MX (1) MXPA03011062A (is)
MY (1) MY129649A (is)
NL (1) NL300887I2 (is)
NO (3) NO328578B1 (is)
NZ (2) NZ540332A (is)
OA (1) OA12612A (is)
PA (1) PA8546301A1 (is)
PE (1) PE20030561A1 (is)
PL (2) PL228155B1 (is)
PT (1) PT1666481E (is)
RS (1) RS52144B (is)
SI (1) SI1666481T1 (is)
SK (2) SK288199B6 (is)
TN (1) TNSN03128A1 (is)
TW (2) TWI310384B (is)
UA (1) UA80093C2 (is)
UY (1) UY27317A1 (is)
WO (1) WO2002096909A1 (is)
ZA (1) ZA200307982B (is)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
UA72290C2 (uk) 1999-12-10 2005-02-15 Пфайзер Продактс Інк. СПОЛУКИ ПІРОЛО[2.3-d]ПІРИМІДИНУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ (ВАРІАНТИ), СПОСІБ ІНГІБУВАННЯ ПРОТЕЇНКІНАЗ АБО JANUS КІНАЗИ 3 (ВАРІАНТИ)
CN100351253C (zh) * 2000-06-26 2007-11-28 辉瑞产品公司 作为免疫抑制剂的吡咯并[2,3－d]嘧啶化合物
GT200200234A (es) 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ATE451104T1 (de) 2002-07-29 2009-12-15 Rigel Pharmaceuticals Inc Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen
ATE402700T1 (de) * 2002-08-27 2008-08-15 Merck Patent Gmbh Glycinamid-derivate als raf-kinase-hemmer
KR20050086784A (ko) 2002-11-26 2005-08-30 화이자 프로덕츠 인크. 이식 거부반응의 치료 방법
ES2421139T3 (es) 2003-07-30 2013-08-29 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
JP2007536310A (ja) * 2004-05-03 2007-12-13 ノバルティス アクチエンゲゼルシャフト Ｓ１ｐ受容体アゴニストおよびｊａｋ３キナーゼ阻害剤を含む、組合せ剤
EP1768982A2 (en) 2004-06-29 2007-04-04 Amgen Inc. Pyrolo [2,3-d] pyrimidines that modulate ack1 and lck activity
BRPI0514094A (pt) 2004-08-02 2008-05-27 Osi Pharm Inc composto, composição, e, método de tratamento de distúrbio hiperproliferativo
WO2006056399A2 (en) * 2004-11-24 2006-06-01 Novartis Ag Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
US7491732B2 (en) 2005-06-08 2009-02-17 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP1910358A2 (en) 2005-07-14 2008-04-16 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
CN101233138A (zh) 2005-07-29 2008-07-30 辉瑞产品公司 吡咯并[2，3-d]嘧啶衍生物、其中间体和合成方法
CA2621261C (en) 2005-09-22 2014-05-20 Incyte Corporation Azepine inhibitors of janus kinases
DK3184526T3 (en) 2005-12-13 2019-01-14 Incyte Holdings Corp PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AS A JANUS-KINASE INHIBITOR
WO2007098507A2 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
GB0605691D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
EP2121692B1 (en) 2006-12-22 2013-04-10 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
DK2740731T3 (en) 2007-06-13 2016-04-11 Incyte Holdings Corp CRYSTALLINE SALTS OF JANUSKINASEINHIBITOREN (R) -3- (4- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-CYCLOPENTYLPROPANNITRIL
KR101258316B1 (ko) 2007-07-11 2013-04-30 화이자 인코포레이티드 안구 건조증 치료용 약학 조성물 및 방법
MX2010008926A (es) 2008-02-15 2011-02-23 Rigel Pharmaceuticals Inc Compuestos de pirimidin-2-amina y su uso como inhibidores de jak cinasas.
BRPI0909040B8 (pt) 2008-03-11 2021-05-25 Incyte Holdings Corp derivados de azetidina e ciclobutano, seus usos, e composição
NZ589315A (en) 2008-04-16 2012-11-30 Portola Pharm Inc 2,6-diamino-pyrimidin-5-yl-carboxamides as Spleen tryosine kinase (syk) or Janus kinase (JAK) inhibitors
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
NZ588830A (en) 2008-04-22 2012-11-30 Portola Pharm Inc Inhibitors of protein kinases
US20110165183A1 (en) * 2008-08-01 2011-07-07 Biocryst Pharmaceuticals, Inc. Piperidine derivatives as jak3 inhibitors
BRPI0917459B1 (pt) 2008-08-20 2017-09-12 Zoetis Services Llc N-methyl-1- [trans-4- [methyl (7h-pyrrol [2,3-d] pyridol [2,3-d] pyrimidine compounds, use of these in therapy and crystalline a form of n-methyl- pyrimidin-4-yl) amino] cyclohexyl} methanosulphonamide
US8592415B2 (en) * 2009-02-11 2013-11-26 Reaction Biology Corp. Selective kinase inhibitors
ES2552805T3 (es) 2009-04-20 2015-12-02 Auspex Pharmaceuticals, Llc Inhibidores piperidínicos de la cinasa Janus 3
MY156727A (en) 2009-05-22 2016-03-15 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
AU2010249443B2 (en) 2009-05-22 2015-08-13 Incyte Holdings Corporation 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as JAK inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
BR112012005382A2 (pt) * 2009-09-10 2016-03-29 Hoffmann La Roche inibidores de jak
KR101921850B1 (ko) 2009-10-09 2018-11-23 인사이트 홀딩스 코포레이션 3-（4-（7Ｈ-피롤로〔2,3-ｄ〕피리미딘-4-일）-1Ｈ-피라졸-1-일）-3-사이클로펜틸프로판니트릴의 하이드록실, 케토 및 글루쿠로나이드 유도체
CA2776028C (en) 2009-10-15 2015-12-01 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
ES2461967T3 (es) 2009-12-18 2014-05-21 Pfizer Inc. Compuestos de pirrolo[2,3-d]pirimidina
CN102712640A (zh) * 2010-01-12 2012-10-03 弗·哈夫曼-拉罗切有限公司 三环杂环化合物、其组合物和应用方法
JP2013518882A (ja) 2010-02-05 2013-05-23 ファイザー・インク ＪＡＫ阻害剤としてのピロロ［２，３−ｄ］ピリミジン尿素化合物
AU2011224484A1 (en) 2010-03-10 2012-09-27 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
MY161078A (en) 2010-05-21 2017-04-14 Incyte Holdings Corp Topical formulation for a jak inhibitor
US9102625B2 (en) 2010-11-01 2015-08-11 Portola Pharmaceuticals, Inc. Nicotinamides as JAK kinase modulators
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
EP2640723A1 (en) 2010-11-19 2013-09-25 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
EP2481411A1 (en) 2011-01-27 2012-08-01 Ratiopharm GmbH Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
EP2481397A1 (en) 2011-01-27 2012-08-01 Ratiopharm GmbH Pharmaceutical compositions comprising tasocitinib
ES2547916T3 (es) 2011-02-18 2015-10-09 Novartis Pharma Ag Terapia de combinación de inhibidores de mTOR/JAK
WO2012135338A1 (en) 2011-03-28 2012-10-04 Ratiopharm Gmbh Processes for preparing tofacitinib salts
US9050342B2 (en) 2011-03-29 2015-06-09 Pfizer Inc. Beneficial effects of combination therapy on cholesterol
CN104610264A (zh) * 2011-04-08 2015-05-13 辉瑞大药厂 结晶和非结晶形式的托法替尼,以及包含托法替尼和渗透增强剂的药物组合物
EP2524688B1 (en) 2011-05-11 2013-05-01 ratiopharm GmbH Composition for modified release comprising ranolazine
KR20140040819A (ko) 2011-06-20 2014-04-03 인사이트 코포레이션 Ｊａｋ 저해제로서의 아제티디닐 페닐, 피리딜 또는 피라지닐 카르복스아미드 유도체
HK1198579A1 (en) 2011-08-10 2015-04-30 Novartis Pharma Ag Jak p13k/mtor combination therapy
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
EP2782579B1 (en) 2011-11-23 2019-01-02 Portola Pharmaceuticals, Inc. Pyrazine kinase inhibitors
US9089574B2 (en) 2011-11-30 2015-07-28 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
US10821111B2 (en) 2011-11-30 2020-11-03 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
EP3170827A1 (en) 2011-12-15 2017-05-24 ratiopharm GmbH Tofacitinib mono-oxalate salt
WO2013173720A1 (en) 2012-05-18 2013-11-21 Incyte Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2014016338A1 (en) 2012-07-25 2014-01-30 Lek Pharmaceuticals D.D. New synthetic route for the preparation of 3-amino-piperidine compounds
US9676756B2 (en) 2012-10-08 2017-06-13 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
PH12020551186B1 (en) 2012-11-15 2024-03-20 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
CN104955803B (zh) * 2012-11-30 2017-11-28 斯洛文尼亚莱柯制药股份有限公司 通过硝基‑四氢吡啶前体制备3‑氨基‑哌啶化合物
US9481679B2 (en) 2012-12-17 2016-11-01 Sun Pharmaceutical Industries Limited Process for the preparation of tofacitinib and intermediates thereof
EP2938616A4 (en) 2012-12-28 2016-06-15 Glenmark Pharmaceuticals Ltd PROCESSING METHOD FOR THE PRODUCTION OF TOFACITINIB AND INTERMEDIATE PRODUCTS THEREOF
MY177476A (en) 2013-02-22 2020-09-16 Pfizer Pyrrolo [2,3-d]pyrimidine derivatives as inhibitors of janus kinases (jak)
JP6397831B2 (ja) 2013-03-06 2018-09-26 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤の製造方法及びその中間体
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
US20140343034A1 (en) 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2014174073A1 (en) 2013-04-26 2014-10-30 Sandoz Ag Sustained release formulations of tofacitinib
KR20160045081A (ko) 2013-08-07 2016-04-26 인사이트 코포레이션 Jak1 억제제용 지속 방출 복용 형태
CN104513248B (zh) * 2013-09-30 2019-05-24 重庆医药工业研究院有限责任公司 一种托法替尼中间体的纯化方法
MD4649C1 (ro) 2013-12-05 2020-04-30 Pfizer Inc. Pirol[2,3-d]pirimidinil, pirol[2,3-b]pirazinil şi pirol[2,3-d]piridinil acrilamide
ES2720066T3 (es) 2013-12-09 2019-07-17 Unichem Lab Ltd Mejora del proceso de preparación de (3R,4R)-(1-bencil-4-metilpiperidín-3-il)-metilamina
US9260438B2 (en) 2014-02-06 2016-02-16 Apotex Inc. Solid forms of tofacitinib salts
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
EP3180344B1 (en) 2014-08-12 2019-09-18 Pfizer Inc Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
HUE064003T2 (hu) 2015-01-20 2024-02-28 Wuxi Fortune Pharmaceutical Co Ltd JAK-gátló
BR112017001516B1 (pt) * 2015-02-17 2023-10-31 Amorepacific Corporation Método de ressolubilização quiral, estereoisômero, método para preparar um composto, composto, composição, e kit de ressolubilização quiral
CN104761556B (zh) * 2015-03-21 2017-06-23 河北国龙制药有限公司 托法替布中间体杂质、托法替布杂质及其合成方法，以及托法替布的质量监控方法
EP3078665A1 (en) * 2015-04-10 2016-10-12 OLON S.p.A. Efficient method for the preparation of tofacitinib citrate
ES2734048T3 (es) 2015-04-29 2019-12-04 Wuxi Fortune Pharmaceutical Co Ltd Inhibidores de Janus cinasas (JAK)
WO2016178110A1 (en) 2015-05-01 2016-11-10 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, pyrrolo[2,3-b]pyridinyl acrylamides and epoxides thereof
MX381994B (es) 2015-05-29 2025-03-13 Wuxi Fortune Pharmaceutical Co Ltd Inhibidor de janus quinasa.
JP6507272B2 (ja) * 2015-07-27 2019-04-24 ユニケム ラボラトリーズ リミテッド トファシチニブ口腔内崩壊錠
KR101771219B1 (ko) * 2015-08-21 2017-09-05 양지화학 주식회사 야누스 키나제 1 선택적 억제제 및 그 의약 용도
WO2017091681A1 (en) 2015-11-24 2017-06-01 Aclaris Therapeutics, Inc. Selective kinase inhibitors
CN105348287A (zh) * 2015-11-30 2016-02-24 宁波立华制药有限公司 一种枸橼酸托法替布的新型合成工艺
KR102565407B1 (ko) * 2016-01-04 2023-08-10 (주)아모레퍼시픽 극성 비양자성 용매를 이용한 n-[4-(1-아미노에틸)-페닐]-술폰아미드 유도체의 카이랄 분할 방법
WO2017125417A1 (en) 2016-01-18 2017-07-27 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Tofacitinib as vaccination immune modulator
EP3478687B1 (en) 2016-06-30 2024-03-20 Daewoong Pharmaceutical Co., Ltd. Pyrazolopyrimidine derivatives as kinase inhibitor
CN106831538B (zh) * 2017-01-22 2019-06-25 苏州楚凯药业有限公司 托法替尼中间体的制备方法
KR102398659B1 (ko) 2017-03-17 2022-05-16 주식회사 대웅제약 카이네이즈 저해제로서의 피롤로트리아진 유도체
CN107602569A (zh) * 2017-10-23 2018-01-19 上海博悦生物科技有限公司 一种新型吡咯并[2,3‑d]嘧啶化合物及其合成方法和用途
KR102078805B1 (ko) 2017-11-30 2020-02-19 보령제약 주식회사 토파시티닙을 포함하는 약제학적 조성물
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
KR102577241B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
MX2020006799A (es) 2017-12-28 2020-09-03 Daewoong Pharmaceutical Co Ltd Derivados de oxi-fluoropiperidina como inhibidor de cinasa.
CN112105608B (zh) 2018-01-30 2023-07-14 因赛特公司 制备(1-(3-氟-2-(三氟甲基)异烟碱基)哌啶-4-酮)的方法
US12161748B2 (en) 2018-01-31 2024-12-10 Twi Biotechnology, Inc. Topical formulations comprising tofacitinib
EP3746086A4 (en) * 2018-01-31 2021-10-20 TWI Biotechnology, Inc. TOPICAL FORMULATIONS INCLUDING TOFACITINIB
SMT202400306T1 (it) 2018-03-30 2024-09-16 Incyte Corp Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak.
KR102131107B1 (ko) * 2019-01-15 2020-07-07 주식회사 다산제약 3-아미노-피페리딘 화합물의 신규한 제조 방법
NL2022471B1 (en) 2019-01-29 2020-08-18 Vationpharma B V Solid state forms of oclacitinib
US12364696B2 (en) 2019-02-27 2025-07-22 Jak Slave Pty Ltd Treatment of autoimmune disease
CA3132109A1 (en) 2019-03-13 2020-09-17 Intas Pharmaceuticals Ltd. Process for preparation of tofacitinib and pharmaceutically acceptable salt thereof
CN113993585B (zh) 2019-03-27 2024-10-01 英矽智能科技知识产权有限公司 双环jak抑制剂及其用途
JP7515510B2 (ja) * 2019-04-05 2024-07-12 ユーハン・コーポレイション （３ｒ，４ｒ）－１－ベンジル－ｎ，４－ジメチルピペリジン－３－アミンまたはその塩の製造方法、およびそれを使用したトファシチニブの製造方法
US20220378707A1 (en) 2019-11-14 2022-12-01 Pfizer Inc. 1-(((2s,3s,4s)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide combinations and oral dosage forms
CN114728963B (zh) * 2019-11-25 2023-10-31 株式会社大熊制药 新型三唑吡啶衍生物和包括其的药物组合物
CN115715194A (zh) 2020-04-04 2023-02-24 辉瑞公司 治疗冠状病毒疾病2019的方法
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
EP4308568A1 (en) * 2021-03-15 2024-01-24 Chiesi Farmaceutici S.p.A. Heterocyclic derivatives as janus kinase inhibitors
CN113549075B (zh) * 2021-06-23 2025-09-23 合肥华方医药科技有限公司 一种枸橼酸托法替布非对映异构体杂质的合成方法
EP4180042A1 (en) 2021-11-15 2023-05-17 Sanovel Ilac Sanayi Ve Ticaret A.S. A film coated tablet comprising micronized tofacitinib

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8403224A (nl) 1984-10-24 1986-05-16 Oce Andeno Bv Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen.
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
US5389509A (en) 1993-10-04 1995-02-14 Eastman Kodak Company Ultrathin high chloride tabular grain emulsions
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
EP0682027B1 (de) 1994-05-03 1997-10-15 Novartis AG Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
JPH07330732A (ja) * 1994-06-10 1995-12-19 Kyorin Pharmaceut Co Ltd 光学活性な３−アミノ−１−ベンジルピペリジン誘導体
US6136596A (en) * 1995-05-19 2000-10-24 University Of Massachusetts Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
DK0831829T3 (da) 1995-06-07 2003-12-15 Pfizer Heterocykliske, ringkondenserede pyrimidinderivater
ES2167586T3 (es) 1995-07-05 2002-05-16 Du Pont Pirimidinonas fungicidas.
JP4146514B2 (ja) 1995-07-06 2008-09-10 ノバルティス アクチエンゲゼルシャフト ピロロピリミジン類およびその製造方法
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
EP0802914B1 (en) 1995-11-14 2001-06-06 PHARMACIA & UPJOHN S.p.A. Aryl- and heteroaryl- purine and pyridopyrimidine derivatives
ES2177925T3 (es) 1996-01-23 2002-12-16 Novartis Ag Pirrolopirimidinas y procedimientos para su preparacion.
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
WO1997032879A1 (de) 1996-03-06 1997-09-12 Novartis Ag 7-ALKYL-PYRROLO[2,3-d]PYRIMIDINE
WO1997049706A1 (en) 1996-06-25 1997-12-31 Novartis Ag SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
WO1998002437A1 (en) 1996-07-13 1998-01-22 Glaxo Group Limited Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
ES2297864T3 (es) 1996-08-23 2008-05-01 Novartis Ag Pirrolopirimidinas sustituidas y procesos para su preparacion.
KR20000057228A (ko) 1996-11-27 2000-09-15 디. 제이. 우드, 스피겔 알렌 제이 축합된 비사이클릭 피리미딘 유도체
ES2301194T3 (es) 1997-02-05 2008-06-16 Warner-Lambert Company Llc Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
JP2001520748A (ja) 1997-03-24 2001-10-30 ファルマシア・アンド・アップジョン・カンパニー Ｊａｋ２／サイトカイン受容体結合の阻害剤を同定する方法
JP2002510687A (ja) 1998-04-02 2002-04-09 ニューロゲン コーポレイション アミノアルキル置換ピロロ［２，３−ｂ］ピリジンおよびピロロ［２，３−ｄ］ピリミジン誘導体：ｃｒｆ１レセプタのモジュレータ
CA2333392A1 (en) 1998-05-28 1999-12-02 Parker Hughes Institute Quinazolines for treating brain tumor
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
PT1087970E (pt) 1998-06-19 2004-06-30 Pfizer Prod Inc Compostos pirrolo¬2,3-d|pirimidina
AU4851599A (en) 1998-06-30 2000-01-17 Parker Hughes Institute Method for inhibiting c-jun expression using jak-3 inhibitors
HUP0103386A3 (en) 1998-08-21 2002-07-29 Parker Hughes Inst St Paul Use of quinazoline derivatives for producing pharmaceutical compositions having jak 3-inhibitor effect
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
UA72290C2 (uk) * 1999-12-10 2005-02-15 Пфайзер Продактс Інк. СПОЛУКИ ПІРОЛО[2.3-d]ПІРИМІДИНУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ (ВАРІАНТИ), СПОСІБ ІНГІБУВАННЯ ПРОТЕЇНКІНАЗ АБО JANUS КІНАЗИ 3 (ВАРІАНТИ)
CN100351253C (zh) 2000-06-26 2007-11-28 辉瑞产品公司 作为免疫抑制剂的吡咯并[2,3－d]嘧啶化合物
GT200200234A (es) * 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
EP1768982A2 (en) * 2004-06-29 2007-04-04 Amgen Inc. Pyrolo [2,3-d] pyrimidines that modulate ack1 and lck activity

Also Published As

Publication number Publication date
EP1666481B9 (en) 2013-05-01
BG66489B1 (bg) 2015-05-29
CU23337B7 (es) 2009-01-20
EP1666481B1 (en) 2012-09-19
KR20080083028A (ko) 2008-09-12
PL409305A1 (pl) 2014-12-22
TW200413370A (en) 2004-08-01
PA8546301A1 (es) 2003-05-14
NO20035201L (no) 2003-11-24
PE20030561A1 (es) 2003-06-23
KR20040003037A (ko) 2004-01-07
JP2004534047A (ja) 2004-11-11
IL158588A0 (en) 2004-05-12
EA012666B1 (ru) 2009-12-30
EA200600575A1 (ru) 2006-08-25
LTC1666481I2 (lt) 2018-06-25
NZ540332A (en) 2007-05-31
NO2017047I1 (no) 2017-09-08
ATE519741T1 (de) 2011-08-15
EP1666481A3 (en) 2006-11-29
JP4381137B2 (ja) 2009-12-09
KR100868814B1 (ko) 2008-11-14
TWI316061B (en) 2009-10-21
GT200200100A (es) 2003-02-11
HUP0400152A3 (en) 2012-12-28
AU2008203170B2 (en) 2009-06-18
KR20060133117A (ko) 2006-12-22
KR20060014459A (ko) 2006-02-15
MA27029A1 (fr) 2004-12-20
SK288192B6 (sk) 2014-06-03
CL2008000762A1 (es) 2008-07-04
EP1666481A2 (en) 2006-06-07
GT200200100AA (es) 2007-07-06
HRP20030943B1 (hr) 2011-11-30
BG108389A (bg) 2005-01-31
BR0209246A (pt) 2004-06-15
KR100869409B1 (ko) 2008-11-21
CZ20033260A3 (en) 2004-03-17
US7301023B2 (en) 2007-11-27
US20040229923A1 (en) 2004-11-18
AU2002304401B2 (en) 2008-04-17
CR10177A (es) 2008-08-19
RS52144B (sr) 2012-08-31
PT1666481E (pt) 2012-12-03
LTPA2017025I1 (lt) 2017-09-11
AR037321A1 (es) 2004-11-03
ES2393385T3 (es) 2012-12-20
EE05332B1 (et) 2010-08-16
LUC00031I2 (is) 2017-10-11
OA12612A (en) 2006-06-09
LUC00031I1 (is) 2017-08-10
HUP0400152A2 (en) 2007-07-30
CA2448281A1 (en) 2002-12-05
ZA200307982B (en) 2004-10-14
CZ304366B6 (cs) 2014-04-02
CY2017028I2 (el) 2018-02-14
HUS1900008I1 (hu) 2020-02-28
SI1666481T1 (sl) 2012-11-30
US20030073719A1 (en) 2003-04-17
IS6993A (is) 2003-10-13
PL367945A1 (en) 2005-03-07
GEP20063784B (en) 2006-04-10
NL300887I2 (nl) 2017-08-31
UA80093C2 (uk) 2007-08-27
MY129649A (en) 2007-04-30
NO328578B1 (no) 2010-03-22
EP1609781A1 (en) 2005-12-28
NO20035201D0 (no) 2003-11-24
EP1392694A1 (en) 2004-03-03
AU2008203170A1 (en) 2008-08-07
EP1609781B1 (en) 2011-08-10
US7432370B2 (en) 2008-10-07
TWI310384B (en) 2009-06-01
NZ530380A (en) 2005-08-26
UY27317A1 (es) 2003-02-28
WO2002096909A1 (en) 2002-12-05
KR100926875B1 (ko) 2009-11-16
SK14652003A3 (sk) 2004-05-04
EA200301193A1 (ru) 2004-04-29
CY1113322T1 (el) 2016-06-22
KR20080002931A (ko) 2008-01-04
SK288199B6 (sk) 2014-06-03
AP2002002550A0 (en) 2002-06-30
AR045680A2 (es) 2005-11-09
AU2002304401C1 (en) 2009-03-05
HRP20030943A2 (en) 2005-08-31
NO20093135L (no) 2003-11-24
FR17C1031I2 (fr) 2018-11-02
EA007251B1 (ru) 2006-08-25
FR17C1031I1 (fr) 2017-10-13
ES2369226T3 (es) 2011-11-28
HU230876B1 (hu) 2018-11-29
PL228155B1 (pl) 2018-02-28
BE2017C032I2 (is) 2021-07-19
CN1729192A (zh) 2006-02-01
CA2448281C (en) 2009-05-05
YU92303A (sh) 2006-08-17
TNSN03128A1 (fr) 2005-12-23
ECSP034865A (es) 2004-01-28
AP1859A (en) 2008-07-02
CY2017028I1 (el) 2018-02-14
DK1666481T3 (da) 2012-10-15
MXPA03011062A (es) 2004-03-19
EE200300594A (et) 2004-04-15

Similar Documents

Publication Publication Date Title
IS3023B (is) 3-((3R,4R)-4-metýl-3-[metýl-(7H-pýrróló[2,3-d]pýrimídín-4-ýl)-amínó]-píperidínýl)-3-oxó-própíónítríl sem prótínkínasahindri
CA2469350A1 (en) 3-{4-methyl-3[methyl-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile mono citrate salt
HUP0400300A3 (en) Pyrrolopyrimidines as protein kinase inhibitors
DK1235830T3 (da) Pyrrolo[2,3-d]pyrimidin-forbindelser som proteinkinaseinhibitorer
AU2003254053A8 (en) Pyrazolopyrimidines as protein kinase inhibitors
NO20041887L (no) Benzomidazoler anvendelige som proteinkinase-inhibitorer
EE200200506A (et) 5-alküülpürido[2,3-d]pürimidiinid kui türosiinkinaasi inhibiitorid
NO20032703D0 (no) Pyrazolforbindelser nyttige som proteinkinaseinhibitorer
NO20031189D0 (no) Pyrazolforbindelser nyttige som proteinkinaseinhibitorer
NO20035728L (no) Pyrrolopyrimidiner som proteinkinaseinhibitorer
AU2003254051A8 (en) Pyrazolopyrimidines as kinase inhibitors
ITMI20010667A0 (it) Composizione assorbiodori in particolare per frigoriferi
DK1317448T4 (da) Pyrazolforbindelser anvendelige som proteinkinaseinhibitorer